Trade with Eva: Analytics in action >>

Wednesday, February 19, 2020

-=Tivity Health (TVTY) reported earnings on Wed 19 Feb 20 (a/h)



Tivity Health CEO Donato J. Tramuto to depart, effective immediately 
The Board has appointed current Director Robert ("Bob") J. Greczyn, Jr. Interim CEO while it conducts a comprehensive CEO search with the assistance of a leading executive search firm. Greczyn has been a member of the Board since 2015 and has over 30 years of experience in leadership roles in managed care and healthcare at some of the nation's leading organizations.

Tivity Health misses by $0.15, reports revs in-line; guides Q1 revs below consensus; guides FY20 revs below consensus
  • Reports Q4 (Dec) earnings of $0.40 per share, excluding non-recurring items, $0.15 worse than the S&P Capital IQ Consensus of $0.55; revenues rose 78.3% year/year to $272.8 mln vs the $275.15 mln S&P Capital IQ Consensus.
    • Revs driven by driven by the addition of Nutrition segment revenues of $113.7 million and an increase in Healthcare segment revenues of $6.0 million.
    • Adjusted EBITDA was $55.5 million and $222.1 million for the fourth quarter and fiscal year 2019, respectively. The Company benefited from cost synergies realized of $5.4 million during the fourth quarter and $9.8 million during the fiscal year. The Company remains on track to deliver on its stated cost synergy and integration goals.
  • Co issues downside guidance for Q1, sees Q1 revs of $335-350 mln vs. $367.05 mln S&P Capital IQ Consensus.
  • Co issues downside guidance for FY20, sees FY20 revs of $1243-1285 mln vs. $1.34 bln S&P Capital IQ Consensus.

  • No comments:

    Post a Comment